Brighton Jones LLC Boosts Stock Position in Becton, Dickinson and Company $BDX

Brighton Jones LLC boosted its stake in shares of Becton, Dickinson and Company (NYSE:BDX) by 257.4% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 6,737 shares of the medical instruments supplier’s stock after purchasing an additional 4,852 shares during the quarter. Brighton Jones LLC’s holdings in Becton, Dickinson and Company were worth $1,160,000 as of its most recent SEC filing.

A number of other hedge funds have also made changes to their positions in the business. Graybill Wealth Management LTD. increased its holdings in shares of Becton, Dickinson and Company by 1.5% in the 2nd quarter. Graybill Wealth Management LTD. now owns 18,733 shares of the medical instruments supplier’s stock valued at $3,227,000 after acquiring an additional 281 shares during the last quarter. CVA Family Office LLC raised its stake in shares of Becton, Dickinson and Company by 79.5% during the 2nd quarter. CVA Family Office LLC now owns 219 shares of the medical instruments supplier’s stock worth $38,000 after buying an additional 97 shares in the last quarter. AG2R LA Mondiale Gestion D Actifs raised its stake in shares of Becton, Dickinson and Company by 8.3% during the 2nd quarter. AG2R LA Mondiale Gestion D Actifs now owns 12,105 shares of the medical instruments supplier’s stock worth $2,085,000 after buying an additional 924 shares in the last quarter. Focus Partners Advisor Solutions LLC raised its stake in shares of Becton, Dickinson and Company by 42.3% during the 2nd quarter. Focus Partners Advisor Solutions LLC now owns 4,500 shares of the medical instruments supplier’s stock worth $775,000 after buying an additional 1,337 shares in the last quarter. Finally, PKO Investment Management Joint Stock Co increased its stake in Becton, Dickinson and Company by 18.5% in the 2nd quarter. PKO Investment Management Joint Stock Co now owns 7,700 shares of the medical instruments supplier’s stock valued at $1,326,000 after purchasing an additional 1,200 shares in the last quarter. Hedge funds and other institutional investors own 86.97% of the company’s stock.

Wall Street Analysts Forecast Growth

BDX has been the subject of several research analyst reports. Morgan Stanley raised their price objective on Becton, Dickinson and Company from $196.00 to $197.00 and gave the company an “overweight” rating in a research note on Monday, August 11th. Argus raised their price objective on Becton, Dickinson and Company from $220.00 to $230.00 in a report on Monday, September 15th. Piper Sandler reiterated a “neutral” rating and issued a $200.00 target price (up previously from $185.00) on shares of Becton, Dickinson and Company in a report on Friday, August 8th. Royal Bank Of Canada reiterated a “sector perform” rating and issued a $211.00 target price on shares of Becton, Dickinson and Company in a report on Thursday, October 16th. Finally, Wall Street Zen upgraded Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a research note on Saturday, August 9th. Three equities research analysts have rated the stock with a Buy rating and nine have assigned a Hold rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $205.40.

Insider Activity at Becton, Dickinson and Company

In other news, Director Claire Fraser sold 917 shares of the company’s stock in a transaction that occurred on Wednesday, September 10th. The stock was sold at an average price of $187.50, for a total transaction of $171,937.50. Following the completion of the transaction, the director directly owned 22,226 shares of the company’s stock, valued at approximately $4,167,375. This represents a 3.96% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders sold 1,838 shares of company stock worth $348,392 over the last three months. 0.36% of the stock is currently owned by corporate insiders.

Becton, Dickinson and Company Stock Up 0.6%

Shares of Becton, Dickinson and Company stock opened at $187.02 on Tuesday. The company has a quick ratio of 0.62, a current ratio of 1.10 and a debt-to-equity ratio of 0.69. The firm has a market cap of $53.61 billion, a P/E ratio of 33.64, a P/E/G ratio of 1.45 and a beta of 0.25. Becton, Dickinson and Company has a fifty-two week low of $163.33 and a fifty-two week high of $251.99. The business has a 50-day moving average price of $189.76 and a 200 day moving average price of $183.63.

Becton, Dickinson and Company (NYSE:BDX) last announced its quarterly earnings data on Thursday, April 14th. The medical instruments supplier reported $4.10 earnings per share for the quarter. The firm had revenue of $5.32 billion during the quarter. Becton, Dickinson and Company had a return on equity of 16.23% and a net margin of 7.51%. On average, sell-side analysts forecast that Becton, Dickinson and Company will post 14.43 earnings per share for the current fiscal year.

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.